Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?

References

• Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
   PubMed Web of Science ®Google Scholar
• Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when east meets west. J Gastroenterol Hepatol. 2009;24:336–345.
   PubMed Web of Science ®Google Scholar
• Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122–132.
   PubMed Web of Science ®Google Scholar
• Huang JF, Chuang WL, Yu ML, et al. Hepatitis C virus infection and metabolic syndrome – a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci. 2009;25:299–305.
   PubMed Web of Science ®Google Scholar
• Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237–1243.
   PubMed Web of Science ®Google Scholar
• Gastaldi G, Goossens N, Clement S, et al. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: a review. J Adv Res. 2017;8:149–159.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Masarone M, Peta V, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol. 2014;20:15233–15240.
   PubMed Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis. J Viral Hepat. 2011;18:745–759.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Bruden D, Bruce MG, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology. 2010;138:922–931 e921.
   PubMed Web of Science ®Google Scholar
• Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18:e516–522.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of. US Veterans with HCV Hepatology. 2014;60:98–105.
   PubMed Web of Science ®Google Scholar
• Monazahian M, Bohme I, Bonk S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol. 1999;57:223–229.
   PubMed Web of Science ®Google Scholar
• Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279–1287.
   PubMed Web of Science ®Google Scholar
• Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1999;96:12766–12771.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Fournier C, Descamps V, et al. Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology. 2017;65:1851–1864.
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Lee LP, Hsieh MY, et al. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis. 2007;60:377–381.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73–80.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428–434.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Patel K, Chuang WL, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012;61:128–134.
   PubMed Web of Science ®Google Scholar
• Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702–726.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461–511.
   PubMed Web of Science ®Google Scholar
• Yu ML, Yeh ML, Tsai PC, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore). 2015;94:e690.
   PubMed Web of Science ®Google Scholar
• Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.
   PubMed Web of Science ®Google Scholar
• McGibbon E, Bornschlegel K, Balter S. Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients. Am J Med. 2013;126:718–722.
   PubMed Web of Science ®Google Scholar
• Denniston MM, Klevens RM, McQuillan GM, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55:1652–1661.
   PubMed Web of Science ®Google Scholar
• Vutien P, Jin M, Le MH, et al. Regional differences in treatment rates for patients with chronic hepatitis C infection: systematic review and meta-analysis. PLoS One. 2017;12:e0183851.
   PubMedGoogle Scholar
• Akinyemiju T, Abera S, Ahmed M, et al.; Global Burden of Disease Liver Cancer C. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–1691.
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Yu ML, Huang CF, Yeh ML, et al. Time-degenerative factors and the risk of hepatocellular Carcinoma after antiviral therapy among hepatitis c virus patients: a model for prioritization of treatment. Clin Cancer Res. 2017;23:1690–1697.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25-32.
   Google Scholar
• Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies – a multicenter prospective trial. J Hepatol. 2011;54:219–226.
   PubMed Web of Science ®Google Scholar
• Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–107 e101.
   PubMed Web of Science ®Google Scholar
• Beste LA, Green PK, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017;67:32–39.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–733.
   PubMed Web of Science ®Google Scholar
• Cheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741–747.
   PubMed Web of Science ®Google Scholar
• [email protected] AcsgohcEa. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734–740.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, et al. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther. 2018;48:664–670.
   PubMed Web of Science ®Google Scholar
• Nahon P, Layese R, Bourcier V, et al. Incidence of Hepatocellular Carcinoma after direct antiviral therapy for HCV in patients with Cirrhosis included in surveillance programs. Gastroenterology. 2018;155:1436-1450.
   Web of Science ®Google Scholar
• Huang JF, Yu ML, Dai CY, et al. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol. 2008;103:1933–1940.
   PubMed Web of Science ®Google Scholar
• Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355–359.
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernandez C, Genesca J, et al. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29:1140–1149.
   PubMed Web of Science ®Google Scholar
• Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279–283.
   PubMed Web of Science ®Google Scholar
• Huang JF, Huang CF, Yeh ML, et al. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. Kaohsiung J Med Sci. 2017;33:567–571.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Nevola R, Guerrera B, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379–1382.
   PubMed Web of Science ®Google Scholar
• Panel A-IHG. Hepatitis C Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection. Clin Infect Dis. 2018;67:1477-1492.
   Google Scholar